Press Releases Janux Therapeutics, Inc.

Equities

JANX

US47103J1051

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-06 pm EDT			5-day change	1st Jan Change
42.59 ^USD	-8.94%		-15.51%	+296.92%

Jun. 06	Janux Therapeutics Insider Sold Shares Worth $45,043,975, According to a Recent SEC Filing	MT
Jun. 06	Janux Therapeutics Insider Sold Shares Worth $82,125,000, According to a Recent SEC Filing	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights	May. 07	BU
Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights	Mar. 08	BU
Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants	Feb. 29	BU
Janux Therapeutics Announces Proposed Public Offering of Common Stock	Feb. 27	BU
Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors	Feb. 26	BU
Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008	Feb. 20	BU
Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer	Jan. 08	BU
Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights	Nov. 07	BU
Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights	23-08-08	BU
Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants	23-07-17	BU
Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs	23-07-17	BU
JANUX THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)	23-06-23	AQ
Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development	23-06-05	BU
JANUX THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	23-05-09	AQ
JANUX THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	23-05-09	AQ
Janux Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights	23-05-09	BU
Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences	23-04-24	BU
Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors	23-04-20	BU
JANUX THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)	23-03-31	AQ
Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights	23-03-13	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Janux Therapeutics, Inc.

Equities

JANX

US47103J1051

Press Releases

Filters